GAIN PC CONTROL is a study investigating Glucagon-Like Peptide-1 Receptor Agonists in men with prostate cancer who are being treated with androgen deprivation therapy.
Have a physician diagnosis of PC
Must be receiving or planned to receive ADT (gonadotropin releasing hormone agonist or antagonist ± androgen receptor pathway inhibitor)
Elevated BMI
≥30kg/m2 or
Type 1 diabetes
Taking a GLP-1 RA
<18 years of age
History of pancreatitis
Single group
Semaglutide Pen Injector
DrugThe semaglutide dose will be 0.25mg subcutaneously once weekly for weeks 1-4, then 0.5mg once weekly for weeks 5-8, then 1mg once weekly for weeks 9-12, then 1.7mg once weekly for weeks 13-16, and then 2.4mg for the remainder of the trial. Semaglutide dose may be decreased in the case of adverse events to the highest tolerated dose.
Number of Serious Adverse Events
An event that leads to death; is life-threatening; results in hospitalization or its prolongation; disability or permanent damage; congenital anomaly or birth defect; or other medical event that is considered serious.
Number of Adverse Events leading to Drug Discontinuation
Adverse Events leading to Drug Discontinuation
Measure of Weight
Measure of Weight
Measure of Waist Circumference
Measure of Waist Circumference
Click on the lead sponsor to view all of their trials.
Hamilton Health Sciences Corporation
Lead sponsor
McMaster University
Collaborator
